Innate Pharma (France) Today
| IPH Stock | EUR 1.53 0.05 3.16% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Innate Pharma is trading at 1.53 as of the 25th of November 2024, a 3.16% down since the beginning of the trading day. The stock's open price was 1.58. Innate Pharma has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Innate Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 80.2 M outstanding shares. More on Innate Pharma
Moving together with Innate Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Innate Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Innate Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Innate Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Herve Brailly |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Innate Pharma (IPH) is traded on Euronext Paris in France and employs 213 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 224.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innate Pharma's market, we take the total number of its shares issued and multiply it by Innate Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Innate Pharma operates under Biotechnology sector and is part of Health Care industry. The entity has 80.2 M outstanding shares.
Innate Pharma has accumulated about 103.76 M in cash with (58.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Innate Pharma Probability Of Bankruptcy
Ownership AllocationInnate Pharma has a total of 80.2 Million outstanding shares. Innate Pharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Innate Ownership Details
Innate Pharma Risk Profiles
Although Innate Pharma's alpha and beta are two of the key measurements used to evaluate Innate Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.66 | |||
| Standard Deviation | 2.32 | |||
| Variance | 5.36 | |||
| Risk Adjusted Performance | (0.14) |
Innate Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Innate Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Innate Pharma Corporate Management
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MBA | VP Founder | Profile | |
| Frederic MBA | VP CFO | Profile | |
| Odile Belzunce | VP Operations | Profile | |
| Mondher MD | Chairman CEO | Profile | |
| Alessandro MD | Founder | Profile | |
| Jean Fourni | Founder | Profile |
Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.